
Marit Renée Myhre
- Research associate; PhD
- +47 22 78 23 18
Education:
2004 2010: PhD in Virology (Faculty of Health Sciences, University of Tromsø, Norway)
A study of the Human Polyomavirus BK Replication and the Role of its Agnoprotein
1997 1999: MSc in Microbiology (Department of Medical Microbiology, University of Tromsø, Norway) Vancomycin-Resistand Enterococci
1993 1997: BSc in Biology (University of Tromsø, Norway)
Research interests/projects:
Pre-clinical study, analysis, and validation of immune treatments mechanisms and effects, as well as in-vivo modelling and verification of novel cell-based therapies
- Therapeutic TCR discovery and pre-clinical validation
- Chimeric Antigen Receptors (CAR) discovery and pre-clinical validation
- Discovery and pre-clinical validation of vaccination targets
- Development of novel technologies to improve cell-based therapy
Work experience
2013 present: Research Fellow, Dept. of Cellular Therapy, OUS-Radiumhospitalet, Oslo, Norway
2009 2013: Research Fellow, Dept. of Immunology, Institute for Cancer Research, OUS-Radiumhospitalet, Oslo, Norway
1999 2004: Research assistant, Department of Medical Microbiology, University of Tromsø, Norway
Publications 2020
Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
Mol Ther (in press)
DOI 10.1016/j.ymthe.2020.11.019, PubMed 33212301
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 69 (1), 159-161
DOI 10.1007/s00262-019-02409-6, PubMed 31776597
Publications 2019
NK cells specifically TCR-dressed to kill cancer cells
EBioMedicine, 40, 106-117
DOI 10.1016/j.ebiom.2019.01.031, PubMed 30665853
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
Oncoimmunology, 8 (3), 1558663
DOI 10.1080/2162402X.2018.1558663, PubMed 30723591
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Cancer Immunol Immunother, 68 (8), 1235-1243
DOI 10.1007/s00262-019-02356-2, PubMed 31214732
Publications 2018
Artesunate shows potent anti-tumor activity in B-cell lymphoma
J Hematol Oncol, 11 (1), 23
DOI 10.1186/s13045-018-0561-0, PubMed 29458389
Publications 2017
T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth
Oncoimmunology, 6 (4), e1302631
DOI 10.1080/2162402X.2017.1302631, PubMed 28507809
Publications 2015
Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model
Gene Ther, 22 (5), 391-403
DOI 10.1038/gt.2015.4, PubMed 25652098
Publications 2009
Clinical polyomavirus BK variants with agnogene deletion are non-functional but rescued by trans-complementation
Virology, 398 (1), 12-20
DOI 10.1016/j.virol.2009.11.029, PubMed 20005552
Publications 2008
Phosphorylation of human polyomavirus BK agnoprotein at Ser-11 is mediated by PKC and has an important regulative function
Virology, 379 (1), 97-109
DOI 10.1016/j.virol.2008.06.007, PubMed 18635245
Publications 2003
Human polyomavirus BK (BKV) transiently transforms and persistently infects cultured osteosarcoma cells
Virus Res, 93 (2), 181-7
DOI 10.1016/s0168-1702(03)00096-0, PubMed 12782366
Publications 2000
Typeability of Tn1546-like elements in vancomycin-resistant enterococci using long-range PCRs and specific analysis of polymorphic regions
Microb Drug Resist, 6 (1), 49-57
DOI 10.1089/mdr.2000.6.49, PubMed 10868807